SRF up-regulation was shown to be an early event during prostate cancer progression, being associated with biochemical recurrence [13], and also a biomarker of progression, with higher levels of SRF associated with castrate resistance [7], decreased survival from diagnosis [12] and response to docetaxel [14]. The gene discussed is SRF; the disease is prostate cancer.